Skip to content

LAMSA2020: “A phase II randomized study to assess the efficacy on outcome of Venetoclax combined with Cytarabine versus Idarubicin combined with Cytarabine administered as post-remission therapy to elderly patients with acute myeloid leukemia in first remission”

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502392-37-00
Enrollment
114
Registered
2024-07-23
Start date
2022-05-25
Completion date
2026-01-05
Last updated
2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elderly patients (> = 60 years) with Acute Myeloid Leukemia

Interventions

None listed

Sponsors

French Innovative Leukemia Organization
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026